StockNasdaqGSVTRS

Viatris

$17.42

+0.42 (+2.47%)today

Valuation & earnings

Forward P/E: 6.52
EPS (ttm): -$0.38
Forward EPS: $2.67
Price/book: 1.38
PEG ratio: 1.05
Dividend yield: 2.8%
Payout ratio: 960%

Financials (ttm)

Revenue (ttm): 14.7B
Revenue growth: 4.9%
Profit margin: -2.79%
Return on equity: -2.75%
Total cash: 1.5B
Total debt: 13.6B

Earnings (EPS)

Quarter	Estimate	Actual	Surprise
Sep 30, 2025	0.62	0.67	+8.52%
Dec 31, 2025	0.53	0.57	+7.39%
Mar 31, 2026	0.5	0.59	+17.54%
Jun 30, 2026	0.6	0.69	+15.04%

Next earnings date: Nov 5, 2026

Analyst view

Consensus ratingBuy12 analysts

Strong buy 1Buy 6Hold 4Strong sell 1

12-month price targetsImplied upside: +11.37%

19.4

LowCurrent priceHigh

Dividends

Dividend yield: 2.8%
Dividend (annual): $0.48
Ex-dividend date: Aug 21, 2026

Recent payments

Aug 21, 2026 · $0.12May 22, 2026 · $0.12Mar 9, 2026 · $0.12Nov 24, 2025 · $0.12Aug 22, 2025 · $0.12

Key stats

Previous close: $17.00
Day range: 17 – 17.45
52-week range: 9.43 – 18.39
Volume: 13.7M
Avg. volume: 9.3M
Market cap: 20B
Beta: 0.88
52-week change: 82.98%
Currency: USD

Profile

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabo(English)

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 30,000
Headquarters: Canonsburg, United States

Visit website

Market data provided by Yahoo Finance, may be delayed. For informational purposes only — not investment advice.